Skip to main content
AB Science logo

AB Science — Investor Relations & Filings

Ticker · AB ISIN · FR0010557264 LEI · 969500U43TVR8CCVBJ97 PA Manufacturing
Open in API
Filings indexed 742 across all filing types
Latest filing 2013-07-03 Share Issue/Capital Cha…
Country FR France
Listing PA AB

About AB Science

https://www.ab-science.com

AB Science is a clinical-stage pharmaceutical company that researches, develops, and markets protein kinase inhibitors for human and veterinary medicine. The company focuses on developing innovative drugs for diseases with high unmet medical needs. Its pipeline is centered on two main compounds: masitinib and AB8939. Masitinib, a highly selective tyrosine kinase inhibitor, is under investigation for treating neurodegenerative disorders such as Amyotrophic Lateral Sclerosis (ALS) and Alzheimer's disease, as well as inflammatory diseases like mastocytosis. AB8939 is a microtubule destabilizer being developed for oncology, specifically for Acute Myeloid Leukemia (AML). The company also commercializes masitinib in veterinary medicine under the brand name Masivet®.

Recent filings

Filing Released Lang Actions
AB Science : Information mensuelle relative aux droits de vote et d'actions
Share Issue/Capital Change Classification · 95% confidence The document is titled 'INFORMATION MENSUELLE RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D'ACTIONS COMPOSANT LE CAPITAL SOCIAL' (Monthly information relating to the total number of voting rights and shares comprising the share capital). It explicitly references Article 221-1 and 223-16 of the AMF General Regulation and provides a table showing the total number of shares and voting rights as of a specific date (June 30, 2013). This content directly relates to the structure of the capital and voting rights, which is a specific regulatory disclosure. While it is a monthly update, it is not a standard earnings release (ER) or interim report (IR). It is a specific disclosure about capital structure and voting rights. Given the options, this type of mandatory disclosure about the total number of shares and voting rights is most closely aligned with general regulatory reporting, but since there is no specific code for 'Total Voting Rights Disclosure', I must evaluate the closest fit. It is not a Director's Dealing (DIRS), nor a Share Issue (SHA) which usually implies a transaction. It is a mandatory disclosure of capital structure components. Since it is a formal, periodic regulatory filing providing specific data points about the company's structure, and it doesn't fit the other specific financial/event codes, the most appropriate general regulatory category is RNS (Regulatory Filings), as it is a required disclosure to the market regulator (AMF). However, looking closely at the definitions, none perfectly match a 'Total Voting Rights Disclosure'. If we consider the content: it details the capital structure and voting rights. This is often a component of a larger filing or a standalone regulatory notice. Given the options, RNS is the best fallback for a mandatory regulatory notice that doesn't fit elsewhere. If 'SHA' (Share Issue/Capital Change) is interpreted broadly to include capital structure reporting, it could fit, but 'SHA' usually implies an action (issue/split). Therefore, RNS remains the most robust fallback for a mandatory, non-financial summary regulatory update.
2013-07-03 French
AB Science : Résultats de l'Assemblée Générale Mixte du 18 juin 2013
Declaration of Voting Results & Voting Rights Announcements Classification · 98% confidence The document text is titled "Résultats de l'Assemblée Générale Mixte du 18 juin 2013" (Results of the Combined General Meeting of June 18, 2013). It details the resolutions voted upon, the results (approved/rejected), and the voting percentages. This content directly corresponds to the official results from a shareholder meeting. The appropriate classification code is AGM-R (AGM Information) or DVA (Declaration of Voting Results & Voting Rights Announcements). Since the document explicitly lists the results of the votes taken at the General Meeting, DVA is the most precise fit, although AGM-R is also highly relevant. Given the focus on the voting outcomes, DVA is selected as the primary classification.
2013-06-19 French
AB Science : Modalités de mise à disposition des informations relatives à l'AGM du 18 juin 2013
AGM Information Classification · 98% confidence The document explicitly announces the details for the 'Assemblée Générale Mixte du 18 juin 2013' (Mixed General Meeting of June 18, 2013). It details the location, date, and availability of related documents (like the agenda and resolutions) as required by French commercial code. This content directly relates to the formal meeting of shareholders, which falls under the scope of AGM Information. Although it mentions the 'avis de réunion' (notice of meeting), the primary focus is informing shareholders about the meeting itself and the associated procedures, making AGM-R the most appropriate classification over a simple RPA or RNS.
2013-06-03 French
AB Science : Launch of a phase 3 clinical trial in Alzheimer's disease
Regulatory Filings Classification · 85% confidence The document is a press release dated May 20, 2013, announcing the launch of a Phase 3 clinical trial for masitinib in Alzheimer's disease and the recruitment of the first patients. It details the study design, summarizes prior Phase 2 results, and provides background information on the disease and the drug. This type of announcement, detailing clinical trial progress and results, is characteristic of corporate communications related to R&D pipeline updates. It is not a formal regulatory filing like a 10-K, an earnings release (ER), or a comprehensive interim report (IR). Since it is a specific announcement about clinical development and trial initiation, it best fits under the general category of Investor Information or a specific regulatory filing if one existed. Given the provided options, this is a specific corporate update that doesn't fit the financial reporting codes (10-K, IR, ER) or governance codes (DEF 14A, CGR). It is a detailed update aimed at investors about a key development. While it could potentially be classified as RNS (Regulatory Filings) as a fallback, the content is highly specific to R&D progress. In the context of standard financial filings, announcements about clinical trial progress are often categorized broadly. Since there is no specific 'Clinical Trial Update' code, and it is a detailed announcement, it is most appropriately classified as a general Regulatory Filing (RNS) or potentially an Investor Presentation (IP) if it were structured as slides, but it reads like a press release. Given the nature of the announcement (launching a trial and reporting on progress), and lacking a better fit, RNS (Regulatory Filings) serves as the most appropriate general category for non-standard, material corporate news releases.
2013-05-20 English
AB Science : Initiation d'une étude clinique de phase 3 dans la maladie d'Alzheimer
Legal Proceedings Report Classification · 99% confidence The document is a press release dated May 20, 2013, announcing the initiation of a Phase 3 clinical study for masitinib in Alzheimer's disease and the recruitment of the first patients. It details the study design (Phase 3, randomized, double-blind), efficacy endpoints (ADAS-Cog, ADCS-ADL), and references prior Phase 2 results. This type of announcement, detailing clinical trial progress and results, is characteristic of an Investor Presentation (IP) or a general press release related to R&D pipeline updates. Since it is a detailed announcement about clinical development rather than a formal financial report (like 10-K or IR) or a transcript, 'Investor Presentation' (IP) is the most fitting category for conveying strategic R&D progress to investors, although it is structured as a press release. Given the detailed scientific and clinical information provided, it goes beyond a simple Earnings Release (ER) or a general Regulatory Filing (RNS). It functions as a detailed update on a key asset, aligning best with the scope of an Investor Presentation.
2013-05-20 French
AB Science : Information mensuelle relative au nombre total de droits de vote au 30/04/2013
Share Issue/Capital Change Classification · 95% confidence The document is titled "INFORMATION MENSUELLE RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D'ACTIONS COMPOSANT LE CAPITAL SOCIAL" (Monthly information relating to the total number of voting rights and shares comprising the share capital). It explicitly references Article 221-1 and 223-16 of the AMF (Autorité des Marchés Financiers) General Regulation. It provides a table showing the total number of shares and voting rights as of a specific date (April 30, 2013). This content directly relates to reporting changes in share capital structure and voting rights, which aligns best with the 'Share Issue/Capital Change' (SHA) category, as it is a mandatory periodic disclosure regarding the capital base. While it is a monthly report, it is not a comprehensive financial report (IR) or an earnings release (ER). It is a specific regulatory disclosure about the capital structure.
2013-05-06 French

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.